Valneva (VALN) Competitors

Valneva has a beta of 1.67, indicating that its share price is 67% more volatile than the broader market. Comparatively, Nektar Therapeutics has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

In the previous week, Nektar Therapeutics had 6 more articles in the media than Valneva. MarketBeat recorded 9 mentions for Nektar Therapeutics and 3 mentions for Valneva. Valneva's average media sentiment score of 0.38 beat Nektar Therapeutics' score of 0.31 indicating that Valneva is being referred to more favorably in the media.

Valneva has a net margin of -110.33% compared to Nektar Therapeutics' net margin of -287.84%. Nektar Therapeutics' return on equity of -37.87% beat Valneva's return on equity.

11.4% of Valneva shares are held by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are held by institutional investors. 14.9% of Valneva shares are held by insiders. Comparatively, 2.5% of Nektar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 39.64%. Nektar Therapeutics has a consensus target price of $141.50, suggesting a potential upside of 102.84%. Given Nektar Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Valneva.

Valneva has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

In the previous week, Valneva had 1 more articles in the media than Precigen. MarketBeat recorded 3 mentions for Valneva and 2 mentions for Precigen. Precigen's average media sentiment score of 1.61 beat Valneva's score of 0.38 indicating that Precigen is being referred to more favorably in the news media.

Valneva has a net margin of -110.33% compared to Precigen's net margin of -183.98%. Precigen's return on equity of 423.75% beat Valneva's return on equity.

Valneva has higher revenue and earnings than Precigen. Precigen is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

Valneva presently has a consensus target price of $9.30, suggesting a potential upside of 39.64%. Precigen has a consensus target price of $14.50, suggesting a potential upside of 111.68%. Given Precigen's stronger consensus rating and higher probable upside, analysts plainly believe Precigen is more favorable than Valneva.

Valneva has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market. Comparatively, Precigen has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 33.5% of Precigen shares are owned by institutional investors. 14.9% of Valneva shares are owned by insiders. Comparatively, 41.4% of Precigen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Biohaven has a net margin of 0.00% compared to Valneva's net margin of -110.33%. Valneva's return on equity of -153.20% beat Biohaven's return on equity.

88.8% of Biohaven shares are owned by institutional investors. Comparatively, 11.4% of Valneva shares are owned by institutional investors. 13.8% of Biohaven shares are owned by company insiders. Comparatively, 14.9% of Valneva shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valneva has higher revenue and earnings than Biohaven. Valneva is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Biohaven has a beta of 1.28, suggesting that its stock price is 28% more volatile than the broader market. Comparatively, Valneva has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market.

In the previous week, Biohaven had 14 more articles in the media than Valneva. MarketBeat recorded 17 mentions for Biohaven and 3 mentions for Valneva. Valneva's average media sentiment score of 0.38 beat Biohaven's score of 0.32 indicating that Valneva is being referred to more favorably in the news media.

Biohaven presently has a consensus price target of $18.69, indicating a potential upside of 46.50%. Valneva has a consensus price target of $9.30, indicating a potential upside of 39.64%. Given Biohaven's stronger consensus rating and higher probable upside, equities analysts plainly believe Biohaven is more favorable than Valneva.

Valneva has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Valneva, indicating that it is currently the more affordable of the two stocks.

11.4% of Valneva shares are owned by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are owned by institutional investors. 14.9% of Valneva shares are owned by company insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Nuvation Bio had 2 more articles in the media than Valneva. MarketBeat recorded 5 mentions for Nuvation Bio and 3 mentions for Valneva. Nuvation Bio's average media sentiment score of 0.40 beat Valneva's score of 0.38 indicating that Nuvation Bio is being referred to more favorably in the news media.

Valneva presently has a consensus price target of $9.30, indicating a potential upside of 39.64%. Nuvation Bio has a consensus price target of $13.00, indicating a potential upside of 112.94%. Given Nuvation Bio's stronger consensus rating and higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Valneva.

Valneva has a beta of 1.67, suggesting that its share price is 67% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.52, suggesting that its share price is 52% more volatile than the broader market.

Nuvation Bio has a net margin of -88.18% compared to Valneva's net margin of -110.33%. Nuvation Bio's return on equity of -46.59% beat Valneva's return on equity.